These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 19102025)
1. Health plan pharmacy director: considerations for treatment and management of RSV disease. Burgoyne DS Manag Care; 2008 Nov; 17(11 Suppl 12):17-8, discussion 18-9. PubMed ID: 19102025 [TBL] [Abstract][Full Text] [Related]
2. Health plan medical director: considerations for prevention and management of RSV disease. Tzeel A Manag Care; 2008 Nov; 17(11 Suppl 12):15-7, discussion 18-9. PubMed ID: 19097559 [TBL] [Abstract][Full Text] [Related]
3. In the trenches: a pediatrician's perspective on prevention and treatment strategies for RSV disease. Frogel MP Manag Care; 2008 Nov; 17(11 Suppl 12):7-12, discussion 18-9. PubMed ID: 19097557 [TBL] [Abstract][Full Text] [Related]
4. Managed care considerations: vulnerable populations and prevention strategies for respiratory syncytial virus disease. Peskin SR Manag Care; 2008 Nov; 17(11 Suppl 12):preceding table of contents. PubMed ID: 19097555 [No Abstract] [Full Text] [Related]
5. Use of respiratory syncytial virus surveillance data to optimize the timing of immunoprophylaxis. Panozzo CA; Stockman LJ; Curns AT; Anderson LJ Pediatrics; 2010 Jul; 126(1):e116-23. PubMed ID: 20547651 [TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab. Reeve CA; Whitehall JS; Buettner PG; Norton R; Reeve DM; Francis F J Paediatr Child Health; 2006 May; 42(5):253-8. PubMed ID: 16712554 [TBL] [Abstract][Full Text] [Related]
9. Administration of the first dose of palivizumab immunoprophylaxis against respiratory syncytial virus in infants before hospital discharge: what is the evidence for its benefit? Geskey JM; Ceneviva GD; Brummel GL; Graff GR; Javier MC Clin Ther; 2004 Dec; 26(12):2130-7. PubMed ID: 15823776 [TBL] [Abstract][Full Text] [Related]
10. Improved outcomes with home-based administration of palivizumab: results from the 2000-2004 Palivizumab Outcomes Registry. Frogel M; Nerwen C; Boron M; Cohen A; VanVeldhuisen P; Harrington M; Groothuis J; Pediatr Infect Dis J; 2008 Oct; 27(10):870-3. PubMed ID: 18776822 [TBL] [Abstract][Full Text] [Related]
11. Respiratory syncytial virus (RSV) loads in premature infants with and without prophylactic RSV fusion protein monoclonal antibody. DeVincenzo JP; Aitken J; Harrison L J Pediatr; 2003 Jul; 143(1):123-6. PubMed ID: 12915838 [TBL] [Abstract][Full Text] [Related]
12. Beyond randomized controlled trials: a "real life" experience of respiratory syncytial virus infection prevention in infancy with and without palivizumab. Mitchell I; Tough S; Gillis L; Majaesic C Pediatr Pulmonol; 2006 Dec; 41(12):1167-74. PubMed ID: 17058279 [TBL] [Abstract][Full Text] [Related]
13. Preventing RSV bronchiolitis in vulnerable infants: the role of palivizumab. Fitzgerald DA Paediatr Respir Rev; 2009 Sep; 10(3):143-7. PubMed ID: 19651385 [TBL] [Abstract][Full Text] [Related]
14. Prophylaxis against respiratory syncytial virus in young children with cystic fibrosis. Giebels K; Marcotte JE; Podoba J; Rousseau C; Denis MH; Fauvel V; Laberge S Pediatr Pulmonol; 2008 Feb; 43(2):169-74. PubMed ID: 18085710 [TBL] [Abstract][Full Text] [Related]
15. The role of immunoprophylaxis in the reduction of disease attributable to respiratory syncytial virus. Meissner HC; Bocchini JA; Brady MT; Hall CB; Kimberlin DW; Pickering LK Pediatrics; 2009 Dec; 124(6):1676-9. PubMed ID: 19948632 [No Abstract] [Full Text] [Related]
16. [Respiratory syncytial immunoprophylaxis with palivizumab]. De Halleux V; Lombet J; Rigo J Rev Med Liege; 2007; 62(5-6):299-302. PubMed ID: 17725198 [TBL] [Abstract][Full Text] [Related]
17. Preventing RSV in pediatric patients: improving the outcome at home. Borell M; Myers J; Rineair S Caring; 2007 Sep; 26(9):34-7. PubMed ID: 17948847 [No Abstract] [Full Text] [Related]